<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id>
<journal-title-group>
<journal-title>Neurotherapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1933-7213</issn>
<issn pub-type="epub">1878-7479</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28940049</article-id>
<article-id pub-id-type="pmc">5794692</article-id>
<article-id pub-id-type="publisher-id">574</article-id>
<article-id pub-id-type="doi">10.1007/s13311-017-0574-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tremlett</surname>
<given-names>Helen</given-names>
</name>
<address>
<email>helen.tremlett@ubc.ca</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Waubant</surname>
<given-names>Emmanuelle</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, </institution><institution>University of British Columbia, </institution></institution-wrap>Vancouver, BC Canada </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution>University of California, </institution></institution-wrap>San Francisco, San Francisco, CA USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<volume>15</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>108</lpage>
<permissions>
<copyright-statement>© The American Society for Experimental NeuroTherapeutics, Inc. 2017</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">Pediatric multiple sclerosis (MS) is a chronic, life-long neurological condition associated with inflammation and degeneration in the brain and spinal cord. Fortunately, &lt; 5% of people with MS have their onset in childhood years. However, studying these very-early-onset cases of MS offers key advantages. In particular, with fewer years lived, children have had a limited range of exposures, potentially enhancing our ability to identify what might cause MS. Further, as the actual timing of the biological MS onset is unknown, the possibility to study these children much closer to the real onset of disease is far greater than in the typical adult with MS. Whether MS (in children or adults) can be prevented is unknown and the available drugs are only modestly effective in modifying the disease course and are not without risk. Emerging evidence is providing insight into the gut microbiota’s potential role in triggering and shaping neurological conditions such as MS. The limited number of studies in humans with MS and absence of prior work in pediatric MS motivated the following 3 fundamental questions, addressed in 2 cross-sectional and 1 longitudinal investigation in children with and without MS: 1) Does the gut microbiota composition differ between children with and without MS? 2) Is there an association between the gut microbiota and host immune markers in children with and without MS? 3) Is the gut microbiota associated with the future risk of a MS relapse?</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1007/s13311-017-0574-3) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Multiple sclerosis</kwd>
<kwd>Pediatric</kwd>
<kwd>Microbiome</kwd>
<kwd>Microbiota</kwd>
<kwd>Relapsing-remitting</kwd>
<kwd>Disease-modifying drugs</kwd>
<kwd>Case–control</kwd>
<kwd>Cross-sectional</kwd>
<kwd>Longitudinal</kwd>
<kwd>Relapse risk</kwd>
<kwd>16S rRNA</kwd>
<kwd>Metagenomics</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The American Society for Experimental NeuroTherapeutics, Inc. 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>